Nucala (mepolizumab) is a medication prescribed for the treatment of severe asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic granulomatosis with polyangiitis (EGPA). It is a monoclonal antibody that works by targeting and neutralizing interleukin-5 (IL-5), a protein that plays a key role in the formation and activation of white blood cells called eosinophils. Uses: Nucala is primarily used to treat severe asthma in patients aged 6 years and older. It is prescribed as an add-on treatment for patients who still experience asthma symptoms despite using other medications. Nucala is also used to treat COPD with a history of exacerbations, and EGPA, a rare autoimmune disease that causes inflammation and damage to various organs and tissues. Dosage: The recommended dose of Nucala for asthma and COPD is 100 mg once every four weeks, administered subcutaneously (under the skin) by a healthcare professional. For EGPA, the recommended dose is 300 mg once every four weeks for the first three doses, followed by 300 mg once every eight weeks thereafter. The dosage may be adjusted based on individual response and/or risk factors. Demographic: Nucala is approved for use in patients aged 6 years and older with severe asthma, COPD with a history of exacerbations, and EGPA. It is not recommended for patients with acute exacerbations of COPD or asthma, or for the treatment of other types of asthma. Side Effects: The most common side effects of Nucala include headache, injection site reactions (pain, redness, swelling, itching), back pain, fatigue, and upper respiratory tract infection. Serious allergic reactions have been reported in some patients, including anaphylaxis (a severe, life-threatening allergic reaction), hypersensitivity, and urticaria (hives). If you experience any symptoms of an allergic reaction, seek medical attention immediately. Interactions: There are currently no known drug interactions with Nucala. However, as with any medication, it is important to inform your healthcare provider of all the medications and supplements you are taking, as well as any medical conditions you have. Generic Options: There are currently no generic versions of Nucala available. However, the medication may become available in generic form after the expiration of its patent, which is expected in 2026. In conclusion, Nucala is a medication that has been shown to be effective in the treatment of severe asthma, COPD, and EGPA. It is important to follow the recommended dosage and inform your healthcare provider of any side effects or allergies. While there are currently no known drug interactions with Nucala, it is important to inform your healthcare provider of all the medications and supplements you are taking, as well as any medical conditions you have.